[go: up one dir, main page]

AR017079A1 - A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE. - Google Patents

A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.

Info

Publication number
AR017079A1
AR017079A1 ARP980104487A ARP980104487A AR017079A1 AR 017079 A1 AR017079 A1 AR 017079A1 AR P980104487 A ARP980104487 A AR P980104487A AR P980104487 A ARP980104487 A AR P980104487A AR 017079 A1 AR017079 A1 AR 017079A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
procedure
same
treatment method
Prior art date
Application number
ARP980104487A
Other languages
Spanish (es)
Original Assignee
West Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Christopher filed Critical West Christopher
Publication of AR017079A1 publication Critical patent/AR017079A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica, un proceso para la preparacion de la misma, un método de tratamiento y su uso, donde dicha composicion farmacéutica comprendemicropartículas poliméricas que incluyen una droga, preferentemente olanzapina, y un ácido graso, cuya composicion puede ser adaptada para proveer unavelocidad de liberacion de droga que es aproximadamente lineal en el tiempo, y que tiene un efecto de liberacion repentina o explosiva insignificante.Pharmaceutical composition, a process for the preparation thereof, a method of treatment and its use, wherein said pharmaceutical composition comprises polymeric particles comprising a drug, preferably olanzapine, and a fatty acid, whose composition can be adapted to provide a speed of release of drug that is approximately linear in time, and that has an insignificant sudden or explosive release effect.

ARP980104487A 1997-09-09 1998-09-09 A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE. AR017079A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system

Publications (1)

Publication Number Publication Date
AR017079A1 true AR017079A1 (en) 2001-08-22

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104487A AR017079A1 (en) 1997-09-09 1998-09-09 A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.

Country Status (10)

Country Link
EP (1) EP1011680A2 (en)
JP (1) JP2001515862A (en)
AR (1) AR017079A1 (en)
AU (1) AU745511B2 (en)
CA (1) CA2302762A1 (en)
GB (1) GB9718986D0 (en)
NO (1) NO20001219L (en)
NZ (1) NZ502710A (en)
WO (1) WO1999012549A2 (en)
ZA (1) ZA987762B (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
ES2169980B1 (en) * 1999-12-17 2003-11-01 Lipotec Sa MICROCAPSULES FOR THE PROLONGED RELEASE OF PHARMACOS.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
PT1532985T (en) 2002-06-25 2017-01-20 Takeda Pharmaceuticals Co Process for producing a sustained-release composition
EP1556086A2 (en) * 2002-10-31 2005-07-27 Pfizer Products Inc. Solid and semi-solid polymeric ionic conjugates
PL1675573T4 (en) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
CN1968700A (en) 2004-04-15 2007-05-23 阿尔克姆斯有限公司 polymer based sustained release device
US20090142404A1 (en) 2004-08-31 2009-06-04 Pfizer Inc Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CL2007002851A1 (en) * 2006-10-05 2008-01-18 M S Panacea Biotec Ltd Injectable composition comprising micro or nanodegradable bio-particles including an active agent, a biodegradable polymer, an agent for intensifying the pharmaceutically acceptable viscosity and excipient; and preparation procedures
NO347209B1 (en) 2006-12-18 2023-07-03 Takeda Pharmaceutical Sustained release composition and method of producing the same
RU2440097C2 (en) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Method of treating insulin-independent diabetes and obesity, osmotic delivery system and method for making it
NO2170279T3 (en) 2007-07-31 2018-05-26
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2011037623A1 (en) 2009-09-28 2011-03-31 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
PH12013500923A1 (en) * 2010-11-25 2016-02-08 Geneora Pharma Shijiazhuang Co Ltd Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (en) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd Aripiprazole Lyophilized Formula
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
JP7286542B2 (en) 2017-01-03 2023-06-05 インターシア セラピューティクス，インコーポレイティド A method comprising continuous administration of a GLP-1 receptor agonist and co-administration of drugs
JP2020511483A (en) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ Sustained-release olanzapine preparation
KR102045721B1 (en) * 2019-03-27 2019-11-18 주식회사 씨트리 Compositions of dispersion phase for preparation of apixaban loaded microsphere and biocompatible polymer based apixaban loaded microsphere prepared therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
PT669128E (en) * 1992-11-17 2000-06-30 Yoshitomi Pharmaceutical A SUSTAINABLE LIBERTACARD SPHERE CONTAINING ANTI-PHYSICIANS AND A PROCESS FOR PRODUCING THE SAME
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
GB9718986D0 (en) 1997-11-12
ZA987762B (en) 2000-02-28
AU8992598A (en) 1999-03-29
EP1011680A2 (en) 2000-06-28
AU745511B2 (en) 2002-03-21
CA2302762A1 (en) 1999-03-18
NZ502710A (en) 2001-09-28
NO20001219D0 (en) 2000-03-09
WO1999012549A2 (en) 1999-03-18
NO20001219L (en) 2000-03-09
WO1999012549A3 (en) 1999-05-06
JP2001515862A (en) 2001-09-25

Similar Documents

Publication Publication Date Title
AR017079A1 (en) A PHARMACEUTICAL COMPOSITION, A PROCEDURE FOR THE PREPARATION OF THE SAME, A TREATMENT METHOD AND ITS USE.
BR9611410A (en) Pharmaceutical method and composition to regulate the concentration of lipids
ES2148198T3 (en) PROCEDURE FOR CRUSHING PHARMACEUTICAL SUBSTANCES.
ES2177022T3 (en) AN ITRACONAZOL THAT EXHIBITS AN IMPROVED SOLUBILITY, A METHOD FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION THAT UNDERSTANDS THE SAME.
MX9201782A (en) PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, SUBSTANTIALLY INSOLUBLE IN WATER, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
BR9808888A (en) Dosage forms and method of improving male erectile dysfunction
DE59601880D1 (en) METHOD FOR PRODUCING HYDROPHILER OR PARTIAL HYDROPHILER, INORGANIC AEROGELE
CO5150154A1 (en) SUBSTRATE COMPOSITION AND METHOD FOR USE FOR THE SEQUESTRAY OF SKIN IRRITANTS
DE3769379D1 (en) INFLAMMATORY ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR CONTROLLING INFLAMMATION.
ES2130638T3 (en) SYSTEM FOR THE RELEASE OF ACTIVE SUBSTANCE, FILMOGEN, VAPORIZABLE, FOR USE IN PLANTS.
BR9510302A (en) Controlled-release pharmaceutical dosage form Method for symptomatic treatment of cough Method for preparing a controlled-release pharmaceutical dosage form composition for use in the symptomatic treatment of cough and application of a controlled-release moguistein dosage form
MX9204268A (en) A COMPOSITION FOR THE PROLONGED AND CONTROLLED RELEASE OF MEDICINAL SUBSTANCES AND A PROCESS TO PREPARE THE SAME.
MX9605419A (en) Liquid detergent containing polyhydroxy fatty acid amide and toluene sulfonate salt.
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
EE9700145A (en) Cycloalkanepyridines, their method of preparation, their use in the manufacture of medicinal products and medicinal products containing these compounds
ATE236627T1 (en) PHARMACEUTICAL PREPARATION CONTAINING EICOSAPENTAENIC ACID AND/OR STEARIDONIC ACID
ES2113095T3 (en) SOLID PREPARATION FOR QUICK RELEASE, ITS PRODUCTION AND ITS USE.
ES2137372T3 (en) ANTIFUNGAL SOLUTION FOR THE NAILS.
FI952230L (en) New arylpropane derivative, process for its preparation and its use as an analgesic agent
ES2141208T3 (en) USE OF AN EFFECTIVE AMOUNT OF ACTIVE SUBSTANCES FOR THE TREATMENT OF MIXED SKIN.
DE4495520T1 (en) Process and pharmaceutical composition for the targeted application of active ingredients
ES2132556T3 (en) NEW DERIVATIVE OF BENZO-TIADIAZINA, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
DE59708495D1 (en) SOLID INSTANT RELEASE PHARMACEUTICAL FORMS AND METHOD FOR THEIR PRODUCTION
ES2070370T3 (en) 3,3'-DITIOBIS (PROPIONIC ACIDS) AND ITS ESTERS.
ITRM930286A0 (en) PHARMACEUTICAL COMPOSITION FOR RECTAL ADMINISTRATION IN THE TREATMENT OF HEADACHE AND RELATED METHOD OF PREPARATION AND USE.